Rankings Pharma & medtech AstraZeneca
AstraZeneca
85
15070100
A view of the same findings, not a new score. How it works
A strong score: the model found few serious problems, but analysts see limited upside from here.
Biggest deductions
- China−5
- Future pipeline−4
- Quality of growth−3
Strengths
- Oncology and pipeline+2
- Earnings and guidance+1
- Dividend from FCF+1
How the score is built
From 100 to 85, step by step: points off for the business, the price and the cracks, back for documented strengths, then three data adjustments.
Start
Score
Hover or select a step to see what drove it. Steps with findings open them below.
Key numbers
As of 2 Nov 2026. Analyst targets tend to be optimistic; read upside as a hint, not a forecast.
- Price
- 186.58 USD
- Median analyst target
- 208.00 USD
- Upside to median
- +11.5%
- Analysts
- 12
- Target range
- 158.00 – 240.00 USD
- 52-week change
- +14%
- P/E (trailing)
- 26.2
- Forward P/E
- 17.5
- PEG
- n/a
Findings
Every deduction and every plus, with its source. Open a step to read them.
Business
Is the company getting stronger, not just bigger? · 4 findings−11 of −30
- −3Quality of growthRevenue rose only 6% in Q2 to USD 15.4bn (18% in 2024); CVRM sales fell 15% due to generic competition to Farxiga in the USA and China's volume-based procurement.
- −4Future pipelineWainua surprisingly failed in phase III against heart disease (ATTR-CM) on 9 July – estimated loss of approx. USD 2.5bn in peak sales; the FDA's advisory committee voted against the breast cancer drug camizestrant in April, and the FDA postponed the decision.
- −2MarginIFRS operating margin 24.4% and net margin 17.0% (TTM) – lower than the most profitable pharma peers despite a gross margin of 82%.
- −2Capital allocationInvestment of approx. USD 50bn in US production and research through 2030 in return for a tariff exemption; analysts expect FCF of USD 9.6bn in 2026 vs 11.8bn in 2025.
Price
Today's multiples against the company's own history and its peers. · 3 findings−4 of −35
- −1Multiples vs own historyEV/EBITDA 13.5 vs 13.0-17.4 in 2022-2025; P/E 23.6 vs 28.2-35.1; P/FCF 23.1 vs 20.5-24.5. At the bottom of the historical range after the price drop.
- −2FCF yieldFCF yield 4.3% (TTM), but only about 3.9% on the expected FCF of 9.6 bn USD in 2026.
- −1PeersForward P/E 14.7 – clearly above Sanofi (8.2), even though AstraZeneca is growing faster.
Cracks
Cash flow, customers, debt, insiders, guidance and what sits behind the headline numbers. · 2 findings−8 of −35
- −5ChinaChina has indicted the former China head Leon Wang and AstraZeneca China for, among other things, illegal data collection, illegal trading and health insurance fraud; fines of 1-5 times the unpaid import duties may follow, and the trial has not been scheduled.
- −3US pricing policy and tariffsThe agreement with the Trump administration requires MFN prices in Medicaid and direct discounts to patients; in return, Section 232 tariffs are only postponed for three years.
Plus
Only documented strengths. · 4 findings+5 of +15
- +2Oncology and pipelineOncology grew 16% in Q2 (Imfinzi, Enhertu, Calquence); JP Morgan calls AstraZeneca's news flow over the next 18 months the richest in the sector, with over USD 10bn in risk-adjusted peak sales.
- +1Earnings and guidanceCore EPS +21% in Q2; guidance for 2026 (mid- to high-single-digit revenue growth and low double-digit core EPS growth) and the target of USD 80bn in revenue in 2030 maintained.
- +1Dividend from FCFThe interim dividend has been raised to USD 1.06; the dividend represents 47% of FCF (TTM).
- +1New launchesBaxdrostat (Baxfendy) approved in the US for treatment-resistant hypertension in May 2026.
Caveats
What the score does not capture, or where the data is weak.
The Nordnet listing is Stockholm (AZN, SEK), but stockanalysis has no data for it, so path and price data are the NYSE listing (USD, direct listing since Feb. 2026); currency is therefore set to USD. No forward P/E history for the NYSE listing, so T2 is based on trailing multiples. IFRS EPS is far below core EPS due to amortization of acquisitions (Alexion). Q3 report 30/10.
Also in Pharma & medtech
The highest scores in the same industry.
